Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (<i>Escherichia coli</i>) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial

Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (<i>Escherichia coli</i>) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial

Background: Prophylactic human papillomavirus (HPV) vaccination substantially alleviates cervical cancer burden. This study aimed to evaluate the safety, tolerability, and immunogenicity of an <i>Escherichia coli</i>-expressed recombinant nonavalent HPV vaccine. Methods: A dose-escalatin...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingwei Wei, Weiwei Han, Jing Zhang, Yongjiang Liu, Hongyang Yu, Jingxin Li, Wenjuan Wang
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Vaccines
Subjects:
human papillomavirus
nonavalent
<i>Escherichia coli</i>
phase 1 clinical trial
safety
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/13/5/511
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items